Staphylococcus Albicans
Cell therapyexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Jan 5, 2022 (NCT05543343)
Timeline
No events for the selected filters.
Indications
Approved for
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05975788 | Phase 4 | Nov 30, 2023 | Peking University |
| NCT05407792 | N/A | Jun 6, 2022 | Shandong Province Qianfoshan Hospital |
| NCT05543343 | N/A | Jan 5, 2022 | Qilu Pharmaceutical Co., Ltd., Shandong University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Qilu Pharmaceutical Co., Ltd. | For profit | 1 | 0 | 1 | 2022 |
| Shandong Province Qianfoshan Hospital | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Shandong University | Academic/Hospital | 1 | 1 | 1 | 2022 |
4 organizations
Page 1 / 1